From: Clinical predictors of pathological good response in locally advanced rectal cancer
Variables | Classification | Tumor response | p | |
---|---|---|---|---|
ypT0–1N0 | ypT2–4N0/ypTanyN + | |||
Gender | 0.523 | |||
Male | 32 | 71 | ||
Female | 25 | 45 | ||
Age (years) | 0.237 | |||
< 60 | 29 | 70 | ||
≥ 60 | 28 | 46 | ||
The distance from anal verge (cm) | 0.007 | |||
< 5 | 33 | 42 | ||
≥ 5 | 24 | 74 | ||
cT classification | < 0.001 | |||
2 | 9 | 1 | ||
3 | 16 | 53 | ||
4 | 32 | 62 | ||
cN classification | 0.513 | |||
0 | 3 | 4 | ||
1 | 17 | 27 | ||
2 | 37 | 85 | ||
Clinical stage | 0.874 | |||
II | 3 | 4 | ||
III | 54 | 112 | ||
Pretreatment CEA (ng/mL) | 0.006 | |||
< 5 | 41 | 58 | ||
≥ 5 | 16 | 58 | ||
Posttreatment CA199 (U/mL) | 0.799 | |||
< 37 | 52 | 106 | ||
≥ 37 | 5 | 10 | ||
Pretreatment CEA (ng/mL) | 0.690 | |||
< 5 | 49 | 97 | ||
≥ 5 | 8 | 19 | ||
Posttreatment CA199 (U/mL) | 0.735 | |||
< 37 | 54 | 110 | ||
≥ 37 | 3 | 6 | ||
Concurrent chemotherapy | 0.127 | |||
Capecitabine | 21 | 57 | ||
Capox | 36 | 59 | ||
CRM | 0.594 | |||
Positive | 28 | 52 | ||
Negative | 29 | 64 | ||
EMVI | 0.450 | |||
Positive | 26 | 60 | ||
Negative | 31 | 56 | ||
The neoadjuvant–surgery interval (day) | 0.002 | |||
< 84 | 25 | 79 | ||
≥ 84 | 32 | 37 | ||
The types of surgical procedures | 0.303 | |||
Dixon | 48 | 104 | ||
Others | 9 | 12 |